{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:34:43Z","timestamp":1783049683549,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) remains a challenging disease with a poor prognosis, necessitating more personalized therapeutic strategies. Retinoic acid receptor (RAR) activation is crucial for myeloid differentiation, but non-APL AML cells resist differentiation induced by the pan-RAR agonist all-trans retinoic acid (ATRA). Am80 (tamibarotene), a specific RARA agonist, has been reported to partially overcome this resistance in AML with high RARA expression. However, its effects on myeloid differentiation, especially in comparison to ATRA, remain understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study we compared the effects of Am80 and ATRA in non-APL AML samples, focusing on subsets with high RARA and\/or RARG expression, using molecular and phenotypic differentiation assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In contrast to previous findings, Am80 showed no advantage over ATRA in inducing differentiation in AML cell lines or primary samples, regardless of RARA and RARG expression levels. Cotreatment with inhibitors of the epigenetic modifiers LSD1 and GCN5, which facilitates retinoid-induced myeloid differentiation, enhanced the effects of both Am80 and ATRA to the same extent, with more pronounced responses observed in RARA-high samples. Gene expression analysis revealed identical molecular responses to Am80 and ATRA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study provides evidence that ATRA can be substituted by the more stable Am80 in retinoid-based AML therapies. It also identifies elevated RARA expression as a potential marker for sensitivity to combination therapy with retinoids and epigenetic inhibitors in AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16388-2","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:46:52Z","timestamp":1782557212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1\/GCN5 inhibition and increased RARA expression"],"prefix":"10.1186","volume":"26","author":[{"given":"Faezeh","family":"Ghazvini Zadegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Stanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"\u00d6lsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setenay Gupse","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Sch\u00fctt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina M.","family":"Schn\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yordan","family":"Sbirkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Stengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg P.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Brioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"11","key":"16388_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/bjc.2014.412","volume":"111","author":"T Schenk","year":"2014","unstructured":"Schenk T, Stengel S, Zelent A. Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer. 2014;111(11):2039\u201345.","journal-title":"Br J Cancer"},{"key":"16388_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fmolb.2019.00114","volume":"6","author":"MR Conserva","year":"2019","unstructured":"Conserva MR, Redavid I, Anelli L, Zagaria A, Specchia G, Albano F. RARG Gene Dysregulation in Acute Myeloid Leukemia. Front Mol Biosci. 2019;6:114.","journal-title":"Front Mol Biosci"},{"issue":"10","key":"16388_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/2159-8290.CD-17-0399","volume":"7","author":"MR McKeown","year":"2017","unstructured":"McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, et al. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARalpha Dependency Targetable by SY-1425, a Potent and Selective RARalpha Agonist. Cancer Discov. 2017;7(10):1136\u201353.","journal-title":"Cancer Discov"},{"issue":"9","key":"16388_CR4","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton S, Cluzeau T, Vigil C, Cook RJ, Rousselot P, Rizzieri DA, et al. Targeting RARA overexpression with tamibarotene, a potent and selective RARalpha agonist, is a novel approach in AML. Blood Adv. 2023;7(9):1858\u201370.","journal-title":"Blood Adv"},{"key":"16388_CR5","unstructured":"Tamibarotene Plus Venetoclax\/Azacitidine. in Participants With Newly Diagnosed AML. https:\/\/clinicaltrialsgov\/study\/NCT04905407."},{"issue":"4","key":"16388_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","volume":"18","author":"T Schenk","year":"2012","unstructured":"Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605\u201311.","journal-title":"Nat Med"},{"issue":"11","key":"16388_CR7","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1038\/s41375-019-0581-y","volume":"33","author":"M Kahl","year":"2019","unstructured":"Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, et al. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia. 2019;33(11):2628\u201339.","journal-title":"Leukemia"},{"issue":"3","key":"16388_CR8","first-page":"564","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining Cancer Dependency Map Cell. 2017;170(3):564\u201376. e16.","journal-title":"Defining Cancer Dependency Map Cell"},{"issue":"7728","key":"16388_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"7757","key":"16388_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, Kryukov GV, Lo CC, Mcdonald ER, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503\u20138.","journal-title":"Nature"},{"issue":"8","key":"16388_CR11","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850\u201364. e9.","journal-title":"Cancer Cell"},{"issue":"4","key":"16388_CR12","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.3324\/haematol.2018.192807","volume":"104","author":"MR McKeown","year":"2019","unstructured":"McKeown MR, Johannessen L, Lee E, Fiore C, di Tomaso E. Antitumor synergy with SY-1425, a selective RARalpha agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia. Haematologica. 2019;104(4):e138\u201342.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"16388_CR13","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1182\/blood-2022-159471","volume":"140","author":"M L\u00fcbbert","year":"2022","unstructured":"L\u00fcbbert M, Schmoor C, Berg T, Kruszewski M, Schittenhelm MM, G\u00f6tze K, et al. Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial). Blood. 2022;140(Supplement 1):9087\u20138.","journal-title":"Blood"},{"issue":"7","key":"16388_CR14","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1078-0432.CCR-20-4054","volume":"27","author":"MM Tayari","year":"2021","unstructured":"Tayari MM, Santos HGD, Kwon D, Bradley TJ, Thomassen A, Chen C, et al. Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. Clin Cancer Res. 2021;27(7):1893\u2013903.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"16388_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","volume":"35","author":"M Wass","year":"2021","unstructured":"Wass M, Gollner S, Besenbeck B, Schlenk RF, Mundmann P, Gothert JR, et al. A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy. Leukemia. 2021;35(3):701\u201311.","journal-title":"Leukemia"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16388-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16388-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16388-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:01:52Z","timestamp":1782558112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16388-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16388"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16388-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics commission at the University Hospital Jena.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"777"}}